News Release

Exiting the pandemic together: achieving global immunity and equity

Peer-Reviewed Publication

Impact Journals LLC


image: Exiting the pandemic together: achieving global immunity and equity view more 

Credit: 2023 Ying et al.

“While vaccination has been successful for the general population, it is crucial not to overlook the needs of immunocompromised individuals.”

BUFFALO, NY- September 8, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on September 1, 2023, entitled, “Exiting the pandemic together: achieving global immunity and equity.”

In this new editorial, researchers Yuxin Ying, Jola Bytyci and Lennard YW Lee from Oxford Medical School discuss their recent investigation into the effectiveness of the third booster vaccine, entitled, “COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.” 

Overall, the study found that the third dose booster improved vaccine effectiveness across various measures. However, the benefits of the booster were not as significant for patients with cancer when compared to the general population. This is because immunocompromised (IC) individuals, including those with cancer, have a diminished response to vaccination. 

As a result, they continue to remain at a high risk of experiencing breakthrough infections and severe cases of COVID-19. Unfortunately, vaccination alone does not provide an adequate level of protection for these groups. Consequently, additional measures such as prophylactic antibodies are internally agreed to be the standard of care to address the ongoing impact of the pandemic on affected individuals.

“This study represents the largest global evaluation of the efficacy of the third dose booster vaccine against SARS-CoV-2.”


Continue reading: DOI: 

Correspondence to: Yuxin Ying


Keywords: COVID-19, immunocompromised, vaccination, breakthrough infection, cancer

About Oncoscience

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit and connect with us on social media:

For media inquiries, please contact

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.